Loading...
Loading...
GH| Name | Value |
|---|---|
| Revenues | 126.9M |
| Cost of Revenue | 47.1M |
| Gross Profit | 79.8M |
| Operating Expense | 225.9M |
| Operating I/L | -146.1M |
| Other Income/Expense | 6.8M |
| Interest Income | 2.1M |
| Pretax | -139.3M |
| Income Tax Expense | 0.6M |
| Net Income/Loss | -139.9M |
Guardant Health, Inc. is a precision oncology company that provides blood tests, data sets, and analytics globally. The company's main revenue streams come from its liquid biopsy-based tests such as Guardant360, GuardantOMNI, and Guardant Reveal, which are used for advanced stage cancer detection and treatment selection. Additionally, it generates income from its development services, including companion diagnostic development, regulatory approval, and clinical study setup for biopharmaceutical companies and medical institutions. Guardant Health also offers the GuardantConnect software-based solution, connecting patients with actionable alterations to relevant clinical trials, further contributing to its revenue.
